Matching articles for "Capvaxive"
Adult Immunization
The Medical Letter on Drugs and Therapeutics • August 17, 2026; (Issue 1761)
The CDC Advisory Committee on Immunization Practices
(ACIP) recommends certain vaccines for adults residing in
the US. The American Academy of Family Physicians has
also recently published an adult...
The CDC Advisory Committee on Immunization Practices
(ACIP) recommends certain vaccines for adults residing in
the US. The American Academy of Family Physicians has
also recently published an adult immunization schedule.
Recommendations for vaccination against COVID-19 and
seasonal influenza will be reviewed separately.
Comparison Chart: Some Vaccines for Adults (online only)
The Medical Letter on Drugs and Therapeutics • August 17, 2026; (Issue 1761)
...
View the Comparison Chart: Some Vaccines for Adults
Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • August 4, 2025; (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • August 4, 2025; (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine
The Medical Letter on Drugs and Therapeutics • October 14, 2024; (Issue 1713)
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal...
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal vaccines are currently available in the
US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and
Prevnar 13 (PCV13) are conjugate vaccines licensed
for use in persons ≥6 weeks old, and Pneumovax 23
(PPSV23) is a pneumococcal polysaccharide vaccine
licensed for use in persons ≥2 years old (see Table 1).